Ignite Creation Date:
2025-12-24 @ 11:33 PM
Ignite Modification Date:
2026-01-10 @ 3:16 PM
Study NCT ID:
NCT06636656
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2025-12-23
First Post:
2024-10-07
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
A Study to Test Whether BI 3032950 Helps People With Ulcerative Colitis
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D003093', 'term': 'Colitis, Ulcerative'}], 'ancestors': [{'id': 'D003092', 'term': 'Colitis'}, {'id': 'D005759', 'term': 'Gastroenteritis'}, {'id': 'D005767', 'term': 'Gastrointestinal Diseases'}, {'id': 'D004066', 'term': 'Digestive System Diseases'}, {'id': 'D015212', 'term': 'Inflammatory Bowel Diseases'}, {'id': 'D003108', 'term': 'Colonic Diseases'}, {'id': 'D007410', 'term': 'Intestinal Diseases'}]}}, 'protocolSection': {'designModule': {'phases': ['PHASE2'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'NA', 'maskingInfo': {'masking': 'NONE'}, 'primaryPurpose': 'TREATMENT', 'interventionModel': 'SINGLE_GROUP', 'interventionModelDescription': 'The study consists of Part A and Part B.'}, 'enrollmentInfo': {'type': 'ACTUAL', 'count': 45}}, 'statusModule': {'overallStatus': 'ACTIVE_NOT_RECRUITING', 'startDateStruct': {'date': '2024-12-11', 'type': 'ACTUAL'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2025-12', 'completionDateStruct': {'date': '2028-02-29', 'type': 'ESTIMATED'}, 'lastUpdateSubmitDate': '2025-12-22', 'studyFirstSubmitDate': '2024-10-07', 'studyFirstSubmitQcDate': '2024-10-07', 'lastUpdatePostDateStruct': {'date': '2025-12-23', 'type': 'ESTIMATED'}, 'studyFirstPostDateStruct': {'date': '2024-10-15', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2026-01-19', 'type': 'ESTIMATED'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Proportion of patients with clinical remission defined by the modified Mayo Score [mSC] with mSC of 0 to 2, including stool frequency subscore [SFS] of 0 or 1, rectal bleeding subscore [RBS] of 0, and centrally-read endoscopy subscore [ESS] of 0 or 1', 'timeFrame': 'Up to Week 12', 'description': 'The modified Mayo score (mMS) consists of 3 components\n\n1. Stool frequency subscore (SFS)\n2. Rectal bleeding subscore (RBS)\n3. Endoscopy subscore (ESS) Each component is graded from 0 = none to 3 = severe. The overall range of the mMS is from 0 to 9 with a higher score indicating a worsening of the symptoms.'}], 'secondaryOutcomes': [{'measure': 'Endoscopic remission (defined as centrally-read ESS of 0)', 'timeFrame': 'Up to Week 12', 'description': 'The endoscopy subscore (ESS) is graded from 0 = none to 3 = severe. The ESS is part of the modified Mayo score.'}, {'measure': 'Clinical response (defined as a decrease from baseline in mMS ≥2 and at least a 30% reduction from baseline, and a decrease in RBS of ≥1 or an absolute RBS of 0 or 1)', 'timeFrame': 'Up to Week 12', 'description': 'The modified Mayo score (mMS) consists of 3 components\n\n1. Stool frequency subscore (SFS)\n2. Rectal bleeding subscore (RBS)\n3. Endoscopy subscore (ESS) Each component is graded from 0 = none to 3 = severe. The overall range of the mMS is from 0 to 9 with a higher score indicating a worsening of the symptoms.'}, {'measure': 'Endoscopic improvement (defined as centrally-read ESS of 0 or 1)', 'timeFrame': 'Up to Week 12', 'description': 'The endoscopy subscore (ESS) is graded from 0 = none to 3 = severe. The ESS is part of the modified Mayo score.'}, {'measure': 'Modified Mayo Score change from baseline', 'timeFrame': 'Up to Week 12', 'description': 'The modified Mayo score (mMS) consists of 3 components\n\n1. Stool frequency subscore (SFS)\n2. Rectal bleeding subscore (RBS)\n3. Endoscopy subscore (ESS) Each component is graded from 0 = none to 3 = severe. The overall range of the mMS is from 0 to 9 with a higher score indicating a worsening of the symptoms.'}, {'measure': 'Stool frequency subscore of 0 or 1', 'timeFrame': 'Up to Week 12', 'description': 'The stool frequency (SFS) is graded from 0 = none to 3 = severe. The SFS is part of the modified Mayo score.'}, {'measure': 'Rectal bleeding subscore of 0', 'timeFrame': 'Up to Week 12', 'description': 'The rectal bleeding subscore (RBS) is graded from 0 = none to 3 = severe. The RBS is part of the modified Mayo score.'}, {'measure': 'Occurrence of treatment-emergent adverse events (AEs)', 'timeFrame': 'Up to Week 12 and up to Week 104'}]}, 'oversightModule': {'oversightHasDmc': False, 'isFdaRegulatedDrug': True, 'isFdaRegulatedDevice': False}, 'conditionsModule': {'conditions': ['Ulcerative Colitis']}, 'referencesModule': {'seeAlsoLinks': [{'url': 'http://www.mystudywindow.com', 'label': 'Related Info'}]}, 'descriptionModule': {'briefSummary': "Adults between 18 and 80 years of age with ulcerative colitis can participate in this study. This is a study for people for whom previous treatment was not successful or who stopped previous treatment. The purpose of this study is to find out whether BI 3032950 helps people with ulcerative colitis.\n\nThis study has 2 parts. In Part A, participants get BI 3032950 as an infusion into a vein every 4 weeks. After 12 weeks, doctors check whether the signs and symptoms of ulcerative colitis have improved. Before the results of this assessment are available, participants move on to Part B and get BI 3032950 as an injection under the skin. Participants whose results show clinical response after 12 weeks can continue treatment with BI 3032950. They get BI 3032950 injections under the skin every 4 weeks for up to 2 years.\n\nParticipants visit their doctors every 4 weeks. During these visits, the doctors check the signs and symptoms of ulcerative colitis. This includes taking blood and stool samples. Doctors also do endoscopies. This is a procedure that uses a tube with a camera to look inside the body.\n\nThe doctors also regularly check participants' health and take note of any unwanted effects."}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'maximumAge': '80 Years', 'minimumAge': '18 Years', 'healthyVolunteers': False, 'eligibilityCriteria': "Inclusion criteria\n\n* Female and male participants aged 18 to 80 years (inclusive) at the time of informed consent,\n* Diagnosis of ulcerative colitis (UC) ≥3 months prior to screening by clinical and endoscopic evidence corroborated by a histopathology report,\n* Inadequate response, loss of response, or intolerance to treatment with biologic/targeted therapy or termination of treatment with biologic/targeted therapy for any other reason,\n* Female participants of childbearing potential must be ready and able to use highly effective methods of birth control and male participants are required to use condoms,\n* Further inclusion criteria apply.\n\nExclusion criteria\n\n* Diagnosis of indeterminate colitis, ischemic colitis, radiation colitis, diverticular disease associated with colitis, microscopic colitis, or Crohn's disease (CD),\n* Findings suggestive of CD (e.g. fistulae, granulomas on biopsy),\n* Evidence of colonic moderate/severe mucosal dysplasia or colonic adenomas, unless properly removed,\n* Gastrointestinal neoplasia, primary sclerosing cholangitis, or known colonic stricture,\n* Evidence of fulminant colitis or toxic megacolon at screening,\n* Current ileal-pouch anal anastomosis, ileostomy, colostomy, or known fixed symptomatic stenosis of the intestine,\n* Previous surgery or anticipated surgical intervention for UC (trial participants with previous colonic surgery may be allowed based on investigator's judgement after discussion with the sponsor),\n* Any current or prior abscesses, unless they have been drained and treated at least 6 weeks prior to first trial drug administration and are not anticipated to require surgery,\n* Further exclusion criteria apply."}, 'identificationModule': {'nctId': 'NCT06636656', 'briefTitle': 'A Study to Test Whether BI 3032950 Helps People With Ulcerative Colitis', 'organization': {'class': 'INDUSTRY', 'fullName': 'Boehringer Ingelheim'}, 'officialTitle': 'Phase IIa, Single-arm, Open-label, Multi-center Clinical Trial to Evaluate the Efficacy, Safety, and Tolerability of Intravenous Induction and Subcutaneous Maintenance Treatment With BI 3032950 in Patients With Moderate to Severe Ulcerative Colitis', 'orgStudyIdInfo': {'id': '1486-0006'}, 'secondaryIdInfos': [{'id': '2023-509544-10-00', 'type': 'REGISTRY', 'domain': 'CTIS (EU)'}, {'id': 'U1111-1300-3640', 'type': 'REGISTRY', 'domain': 'WHO International Clinical Trials Registry Platform (ICTRP)'}]}, 'armsInterventionsModule': {'armGroups': [{'type': 'EXPERIMENTAL', 'label': 'All participants', 'description': 'All participants will receive an intravenous dose of BI 3032950 in Part A followed by a subcutaneous dose of BI 3032950 in Part B.', 'interventionNames': ['Drug: BI 3032950 intravenous (Part A)', 'Drug: BI 3032950 subcutaneous (Part B)']}], 'interventions': [{'name': 'BI 3032950 intravenous (Part A)', 'type': 'DRUG', 'description': 'BI 3032950 intravenous (Part A)', 'armGroupLabels': ['All participants']}, {'name': 'BI 3032950 subcutaneous (Part B)', 'type': 'DRUG', 'description': 'BI 3032950 subcutaneous (Part B)', 'armGroupLabels': ['All participants']}]}, 'contactsLocationsModule': {'locations': [{'zip': '85258', 'city': 'Scottsdale', 'state': 'Arizona', 'country': 'United States', 'facility': 'One of a Kind Clinical Research Center', 'geoPoint': {'lat': 33.50921, 'lon': -111.89903}}, {'zip': '80907', 'city': 'Colorado Springs', 'state': 'Colorado', 'country': 'United States', 'facility': 'Peak Gastroenterology Associates', 'geoPoint': {'lat': 38.83388, 'lon': -104.82136}}, {'zip': '34741', 'city': 'Kissimmee', 'state': 'Florida', 'country': 'United States', 'facility': 'Clinical Research of Osceola', 'geoPoint': {'lat': 28.30468, 'lon': -81.41667}}, {'zip': '34211', 'city': 'Lakewood Rch', 'state': 'Florida', 'country': 'United States', 'facility': 'Florida Research Institute', 'geoPoint': {'lat': 27.3863, 'lon': -82.4332}}, {'zip': '33136', 'city': 'Miami', 'state': 'Florida', 'country': 'United States', 'facility': 'University of Miami', 'geoPoint': {'lat': 25.77427, 'lon': -80.19366}}, {'zip': '33165-3639', 'city': 'Miami', 'state': 'Florida', 'country': 'United States', 'facility': 'Reliant Medical Research', 'geoPoint': {'lat': 25.77427, 'lon': -80.19366}}, {'zip': '60031', 'city': 'Gurnee', 'state': 'Illinois', 'country': 'United States', 'facility': 'Illinois Gastroenterology Group - Gurnee', 'geoPoint': {'lat': 42.3703, 'lon': -87.90202}}, {'zip': '66103-2937', 'city': 'Kansas City', 'state': 'Kansas', 'country': 'United States', 'facility': 'University of Kansas Medical Center', 'geoPoint': {'lat': 39.11417, 'lon': -94.62746}}, {'zip': '10032-3725', 'city': 'New York', 'state': 'New York', 'country': 'United States', 'facility': 'Columbia University Medical Center', 'geoPoint': {'lat': 40.71427, 'lon': -74.00597}}, {'zip': '28204-2963', 'city': 'Charlotte', 'state': 'North Carolina', 'country': 'United States', 'facility': 'Atrium Health', 'geoPoint': {'lat': 35.22709, 'lon': -80.84313}}, {'zip': '78613', 'city': 'Cedar Park', 'state': 'Texas', 'country': 'United States', 'facility': 'Texas Digestive Disease Consultants', 'geoPoint': {'lat': 30.5052, 'lon': -97.82029}}, {'zip': '77030', 'city': 'Houston', 'state': 'Texas', 'country': 'United States', 'facility': 'Baylor College of Medicine', 'geoPoint': {'lat': 29.76328, 'lon': -95.36327}}, {'zip': '76063', 'city': 'Mansfield', 'state': 'Texas', 'country': 'United States', 'facility': 'GI Alliance', 'geoPoint': {'lat': 32.56319, 'lon': -97.14168}}, {'zip': '98195-0001', 'city': 'Seattle', 'state': 'Washington', 'country': 'United States', 'facility': 'University of Washington', 'geoPoint': {'lat': 47.60621, 'lon': -122.33207}}, {'zip': '98405-2318', 'city': 'Tacoma', 'state': 'Washington', 'country': 'United States', 'facility': 'Digestive Health Specialists', 'geoPoint': {'lat': 47.25288, 'lon': -122.44429}}, {'zip': '3000', 'city': 'Leuven', 'country': 'Belgium', 'facility': 'UZ Leuven', 'geoPoint': {'lat': 50.87959, 'lon': 4.70093}}, {'zip': '4000', 'city': 'Liège', 'country': 'Belgium', 'facility': 'CHC MontLegia', 'geoPoint': {'lat': 50.63373, 'lon': 5.56749}}, {'zip': '500 12', 'city': 'Hradec Králové', 'country': 'Czechia', 'facility': 'Hepato-Gastroenterologie HK, s.r.o.', 'geoPoint': {'lat': 50.20923, 'lon': 15.83277}}, {'zip': '708 52', 'city': 'Ostrava', 'country': 'Czechia', 'facility': 'University Hospital Ostrava', 'geoPoint': {'lat': 49.83465, 'lon': 18.28204}}, {'zip': '190 00', 'city': 'Prague', 'country': 'Czechia', 'facility': 'ISCARE a.s.', 'geoPoint': {'lat': 50.08804, 'lon': 14.42076}}, {'zip': '30-363', 'city': 'Krakow', 'country': 'Poland', 'facility': 'Centrum Medyczne Plejady', 'geoPoint': {'lat': 50.06143, 'lon': 19.93658}}, {'zip': '20-582', 'city': 'Lublin', 'country': 'Poland', 'facility': 'Medrise Sp. z o.o.', 'geoPoint': {'lat': 51.25058, 'lon': 22.57009}}, {'zip': '95-200', 'city': 'Pabianice', 'country': 'Poland', 'facility': 'Eskulap Pabianice Sp. z o.o.', 'geoPoint': {'lat': 51.66446, 'lon': 19.35473}}, {'zip': '60-309', 'city': 'Poznan', 'country': 'Poland', 'facility': 'EMC Instytut Medyczny S.A. - Poznan 70-304', 'geoPoint': {'lat': 52.40692, 'lon': 16.92993}}, {'zip': '61-731', 'city': 'Poznan', 'country': 'Poland', 'facility': 'Clinical Research Center Sp. z o.o. Medic-R sp.k.', 'geoPoint': {'lat': 52.40692, 'lon': 16.92993}}, {'zip': '35-326', 'city': 'Rzeszów', 'country': 'Poland', 'facility': 'Centrum Medyczne Medyk Sp. z o.o.', 'geoPoint': {'lat': 50.04132, 'lon': 21.99901}}, {'zip': '81-756', 'city': 'Sopot', 'country': 'Poland', 'facility': 'Endoskopia Sp. z o.o.', 'geoPoint': {'lat': 54.4418, 'lon': 18.56003}}, {'zip': '71-434', 'city': 'Szczecin', 'country': 'Poland', 'facility': 'Twoja Przychodnia Szczecinskie Centrum Medyczne Sp. z o.o.', 'geoPoint': {'lat': 53.42894, 'lon': 14.55302}}, {'zip': '87-100', 'city': 'Torun', 'country': 'Poland', 'facility': 'Gastromed Sp. z o.o.', 'geoPoint': {'lat': 53.01375, 'lon': 18.59814}}, {'zip': '02-672', 'city': 'Warsaw', 'country': 'Poland', 'facility': 'Synexus Polska Sp. z o.o.', 'geoPoint': {'lat': 52.22977, 'lon': 21.01178}}, {'zip': '03-580', 'city': 'Warsaw', 'country': 'Poland', 'facility': 'NZOZ VIVAMED Jadwiga Miecz', 'geoPoint': {'lat': 52.22977, 'lon': 21.01178}}, {'zip': '52-210', 'city': 'Wroclaw', 'country': 'Poland', 'facility': 'PlanetMed Sp. z o.o.', 'geoPoint': {'lat': 51.10286, 'lon': 17.03006}}, {'zip': '54-144', 'city': 'Wroclaw', 'country': 'Poland', 'facility': 'EMC Instytut Medyczny S.A. - Wroclaw 54-144', 'geoPoint': {'lat': 51.10286, 'lon': 17.03006}}, {'zip': '87-800', 'city': 'Włocławek', 'country': 'Poland', 'facility': 'Centrum Diagnostyczno Lecznicze Barska Sp. z o.o.', 'geoPoint': {'lat': 52.64817, 'lon': 19.0678}}, {'zip': '22-400', 'city': 'Zamość', 'country': 'Poland', 'facility': 'Pro Life Medica Sp. z o.o.', 'geoPoint': {'lat': 50.72314, 'lon': 23.25196}}, {'zip': '11000', 'city': 'Belgrade', 'country': 'Serbia', 'facility': 'Clinical Hospital Center Dr. Dragisa Misovic', 'geoPoint': {'lat': 44.80401, 'lon': 20.46513}}, {'zip': '11000', 'city': 'Belgrade', 'country': 'Serbia', 'facility': 'Clinical Hospital Center Zvezdara', 'geoPoint': {'lat': 44.80401, 'lon': 20.46513}}, {'zip': '11040', 'city': 'Belgrade', 'country': 'Serbia', 'facility': 'Military Medical Academy', 'geoPoint': {'lat': 44.80401, 'lon': 20.46513}}, {'zip': '11080', 'city': 'Belgrade', 'country': 'Serbia', 'facility': 'Clinical Center Zemun', 'geoPoint': {'lat': 44.80401, 'lon': 20.46513}}, {'zip': '34000', 'city': 'Kragujevac', 'country': 'Serbia', 'facility': 'University Clinical Center of Kragujevac', 'geoPoint': {'lat': 44.01667, 'lon': 20.91667}}, {'zip': '23101', 'city': 'Zrenjanin', 'country': 'Serbia', 'facility': 'General Hospital - Djordje Joanovic', 'geoPoint': {'lat': 45.38361, 'lon': 20.38194}}, {'zip': '975 17', 'city': 'Banská Bystrica', 'country': 'Slovakia', 'facility': 'F D Roosevelt University General Hospital Of Banska Bystrica', 'geoPoint': {'lat': 48.73947, 'lon': 19.14932}}, {'zip': '040 13', 'city': 'Košice', 'country': 'Slovakia', 'facility': 'ENDOMED s.r.o.', 'geoPoint': {'lat': 48.71441, 'lon': 21.25802}}, {'zip': '949 01', 'city': 'Nitra', 'country': 'Slovakia', 'facility': 'KM Management, spol. s.r.o.', 'geoPoint': {'lat': 48.30763, 'lon': 18.08453}}, {'zip': '080 01', 'city': 'Prešov', 'country': 'Slovakia', 'facility': 'Gastro I., s.r.o', 'geoPoint': {'lat': 48.99923, 'lon': 21.2355}}, {'zip': '936 01', 'city': 'Šahy', 'country': 'Slovakia', 'facility': 'Accout Center s.r.o.', 'geoPoint': {'lat': 48.07408, 'lon': 18.94946}}]}, 'ipdSharingStatementModule': {'url': 'https://www.mystudywindow.com/msw/datasharing', 'infoTypes': ['STUDY_PROTOCOL', 'SAP', 'CSR'], 'timeFrame': 'One year after the approval has been granted by major Regulatory Authorities and after the primary manuscript has been accepted for publication, or after termination of the development program.', 'ipdSharing': 'YES', 'description': 'Once the criteria in section \'time frame\' are fulfilled, researchers can use the following link https:// www.mystudywindow.com/msw/datasharing to request access to the clinical study documents regarding this study, and upon a signed "Document Sharing Agreement". Furthermore, researchers can request access to the clinical study data, for this and other listed studies, after the submission of a research proposal and according to the terms outlined in the website.', 'accessCriteria': "For study documents -upon signing of a 'Document Sharing Agreement'. For study data -1. after the submission and approval of the research proposal (checks will be performed by the sponsor and/or the independent review panel, including checking that the planned analysis does not compete with sponsor's publication plan); 2. and upon signing of a legal agreement."}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Boehringer Ingelheim', 'class': 'INDUSTRY'}, 'responsibleParty': {'type': 'SPONSOR'}}}}